Regulatory Alert: The FDA has announced a delay to the effective date of its February 6, 2026, final order expanding the approved use of spirulina extract as a color additive in human foods. If your organization manufactures, formulates, or labels food products using natural colorants, this regulatory change directly affects your compliance timeline and product documentation.
What Happened: The Spirulina Extract Color Additive Final Order
On February 6, 2026, the FDA issued a final order amending the color additive regulations to expand the safe use of spirulina (Arthrospira platensis) extract as a color additive in human foods generally. This represented a significant expansion from the previously limited approved applications for spirulina extract.
However, on March 24, 2026, the FDA published a notice in the Federal Register (Document No. 2026-05733) announcing a delay of the effective date of that February 6, 2026, final order. This delay affects food manufacturers, formulators, and labeling teams who had already begun preparing for compliance with the expanded use provisions.
Citation hook: The FDA's March 24, 2026 Federal Register notice (Document No. 2026-05733) formally delayed the effective date of the February 6, 2026 final order that would have expanded spirulina extract's approved use as a color additive in most human foods.
This type of regulatory delay — particularly one issued just weeks after a final order — signals that manufacturers should maintain heightened monitoring of FDA rulemaking activity before committing to formulation or labeling changes.
Understanding the Regulatory Framework: Color Additives Exempt from Certification
To fully appreciate what this delay means, it helps to understand how the FDA classifies color additives.
Certified vs. Exempt Color Additives
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations at 21 CFR Parts 73 and 74, color additives are divided into two categories:
| Category | Description | Examples | Certification Required? |
|---|---|---|---|
| Certified Color Additives | Synthetically derived; subject to batch-by-batch FDA certification | FD&C Red No. 40, Blue No. 1 | Yes — each batch must be certified |
| Exempt Color Additives | Derived from natural sources; exempt from batch certification | Beet juice, annatto, turmeric | No batch certification required |
| Spirulina Extract | Derived from Arthrospira platensis; natural source | Blue-green colorant | Exempt — no batch certification required |
Spirulina extract falls under 21 CFR Part 73, the listing of color additives exempt from certification. Its use as a colorant in foods is permitted because it is derived from a natural source — the cyanobacterium Arthrospira platensis — and produces blue-green hues that are increasingly sought after by manufacturers responding to consumer demand for clean-label and natural ingredient products.
What the February 2026 Final Order Would Have Changed
Prior to the February 6, 2026, final order, spirulina extract had more limited approved uses. The final order was intended to expand its safe use to human foods generally, with three notable exclusions:
- Infant formula — excluded from the expanded use authorization
- Certain USDA-regulated foods — foods subject to regulation by the U.S. Department of Agriculture
- Foods with standards of identity issued under Section 401 of the FD&C Act — standardized foods where compositional integrity is defined by regulation
This expansion would have been a meaningful development for food manufacturers seeking to replace synthetic colorants with natural alternatives in a broader range of product categories — from beverages and confections to dairy alternatives and snack foods.
Why the Effective Date Was Delayed
The FDA's delay of the effective date is consistent with a broader federal policy directive requiring agencies to review recently issued rules before they take effect. This type of delay is typically issued to allow additional time for:
- Regulatory review under executive oversight directives
- Stakeholder comment if the agency determines further input is warranted
- Interagency coordination, particularly given the USDA carve-out in the original order
- Administrative reconsideration of the rule's scope or implementation timeline
Citation hook: When the FDA delays the effective date of a final food additive order within weeks of its issuance, it signals a period of regulatory uncertainty during which manufacturers should pause formulation changes and await further agency guidance before updating product labels or specifications.
As of the date of this article, manufacturers should treat the expanded use provisions of the February 6, 2026 final order as not yet in effect and continue operating under the previously applicable color additive regulations for spirulina extract.
What This Means for Food Manufacturers: A Compliance Risk Snapshot
The practical compliance implications of this delay vary depending on where your organization is in the product development or reformulation cycle.
If You Had Already Begun Formulating Under the Expanded Use Provisions
Stop and reassess. Any product formulation, label, or specification change made in anticipation of the February 6, 2026 effective date must be placed on hold until the FDA confirms the new effective date or issues a revised final order. Using a color additive in a manner not currently authorized under 21 CFR Part 73 — regardless of a pending or delayed rule — constitutes a violation of the FD&C Act.
If You Were in the Planning Phase
This is the time to build regulatory monitoring into your product development process. Delays like this one are not uncommon in the current regulatory environment. A robust color additive compliance program should include:
- Real-time monitoring of FDA Federal Register notices
- Version-controlled specification sheets tied to specific regulatory authorizations
- Clear internal escalation protocols when a rule is delayed or revised
If You Manufacture Products in the Excluded Categories
If your products include infant formula, USDA-regulated foods (such as meat, poultry, or egg products), or standardized foods under FD&C Act Section 401, the expanded use provisions did not apply to you in the first place. Your existing compliance posture for spirulina extract use in these categories remains unchanged.
Key Dates and Deadlines at a Glance
| Date | Event |
|---|---|
| February 6, 2026 | FDA issues final order expanding spirulina extract use in human foods generally |
| March 24, 2026 | FDA publishes delay of effective date (Federal Register Doc. 2026-05733) |
| TBD | New effective date to be announced by FDA upon completion of review |
Action required: Manufacturers should subscribe to FDA Federal Register notifications and monitor 21 CFR Part 73 amendment activity to receive timely notice of the revised effective date.
Practical Compliance Guidance: Six Steps to Take Right Now
Whether you are a quality manager, regulatory affairs professional, or food safety team lead, here is a structured response plan for this delay:
Step 1: Audit Your Current Spirulina Extract Use
Document every product in your portfolio that currently uses or is planned to use spirulina extract. Cross-reference each product against the currently effective version of 21 CFR Part 73 to confirm authorized use. Do not rely on the February 6, 2026 final order until a new effective date is officially confirmed.
Step 2: Freeze Any Pending Label Updates
If your team was preparing label changes to reflect expanded spirulina extract use, issue an immediate hold on those changes. Submitting or printing labels that reference or imply compliance with a rule not yet in effect creates legal and regulatory exposure.
Step 3: Update Your Regulatory Change Management Log
Log this delay as an open regulatory change item in your change management system. Assign an owner, set a review cadence (monthly, at minimum), and establish a trigger for action once the FDA publishes a revised effective date.
Step 4: Review Supplier Specifications
If your ingredient suppliers have updated their spirulina extract specifications or Certificates of Analysis to reflect the anticipated expanded use authorization, request clarification on whether those documents will be revised given the delay. Your incoming ingredient specifications should align with currently authorized uses only.
Step 5: Brief Your Formulation and Marketing Teams
One of the most common compliance failures I see across the 200+ clients I have supported at Certify Consulting is a disconnect between the regulatory team and the commercial/formulation teams. Marketing and R&D may not monitor Federal Register notices. Make sure they understand that the expanded spirulina authorization is not currently in effect.
Step 6: Monitor for the Revised Effective Date
Set up automated alerts for: - FDA Federal Register notices related to 21 CFR Part 73 - FDA Color Additive Status List updates - Any new FDA guidance documents on spirulina extract or natural color additives
The Broader Context: Natural Color Additives Under Scrutiny
Citation hook: The FDA's expanded authorization of spirulina extract — and the regulatory attention it has attracted — reflects a broader industry and agency trend toward natural color additive approvals, with the global natural food colors market projected to exceed $3.5 billion by 2028, according to industry market research.
Consumer demand for clean-label products with naturally derived colorants has accelerated investment in ingredients like spirulina extract, beet powder, turmeric, and butterfly pea flower. This demand is driving a corresponding increase in FDA rulemaking activity around natural color additives.
At the same time, the FDA is operating under heightened scrutiny from executive oversight bodies, which is contributing to delays and reviews of recently issued rules across multiple regulatory domains — not just food additives.
For manufacturers, this environment creates a compliance paradox: consumer and commercial pressure to adopt natural colorants is high, while the regulatory pathway for those colorants is experiencing more turbulence than usual. The lesson is to build regulatory flexibility into product development timelines — never assume a final order is final until it is in effect.
How ISO 13485 and Quality Management Principles Apply
While ISO 13485 is specifically scoped to medical device quality management systems, the underlying quality management principles it embodies — particularly around regulatory change monitoring, document control, and supplier qualification — are directly applicable to food manufacturers navigating this type of regulatory delay.
Specifically, the principles of:
- Document control (knowing which version of a regulation governs your product)
- Change management (not implementing changes until they are formally authorized)
- Supplier qualification (ensuring your ingredient suppliers are aligned with current regulatory status)
- Management review (escalating regulatory changes to leadership)
...are universal quality system disciplines. If you are a manufacturer that operates under both food safety and medical device quality frameworks, this event is a reminder that regulatory vigilance must be embedded in your QMS — not treated as a one-time compliance exercise.
For deeper guidance on building regulatory change management into a quality management system, explore our resources at iso13485expert.com.
Summary: What You Need to Do
The FDA's delay of the spirulina extract color additive expansion is a timely reminder that regulatory timelines are never guaranteed — and that compliance programs must be built to absorb that uncertainty without creating product or legal liability.
Here is the bottom line: - The February 6, 2026 final order expanding spirulina extract use in human foods is not currently in effect - The delay was announced March 24, 2026 via Federal Register Document No. 2026-05733 - No new effective date has been confirmed as of the publication of this article - Manufacturers should pause any formulation or labeling changes that relied on the February order - Active monitoring of 21 CFR Part 73 amendments is essential
If your organization needs support building a regulatory change management process that prevents compliance gaps like this from becoming product or enforcement issues, the team at Certify Consulting has helped more than 200 clients build quality and regulatory systems that hold up under audit — and under regulatory uncertainty.
Frequently Asked Questions
Is the expanded use of spirulina extract currently authorized under FDA regulations?
No. As of March 24, 2026, the FDA delayed the effective date of the February 6, 2026 final order that would have expanded spirulina extract's authorized use in human foods. Until the FDA announces a new effective date, manufacturers must comply with the previously applicable version of 21 CFR Part 73.
Does the delay affect the use of spirulina extract in infant formula?
No — infant formula was explicitly excluded from the expanded use authorization in the February 6, 2026 final order. The delay of that order has no practical effect on infant formula manufacturers, since the expansion never applied to them.
What should food manufacturers do while the effective date is pending?
Manufacturers should freeze any formulation or labeling changes that were premised on the February 2026 rule, audit current spirulina extract use against the currently effective version of 21 CFR Part 73, and establish a monitoring process to track when the FDA announces a revised effective date.
Does this delay affect other color additives exempt from certification?
The March 24, 2026 delay is specific to the spirulina extract final order (Federal Register Doc. 2026-05733). Other color additives listed under 21 CFR Part 73 are not affected by this delay.
Where can I find the official text of the delay notice?
The official delay notice was published in the Federal Register on March 24, 2026, as Document No. 2026-05733. It is publicly available at federalregister.gov.
Last updated: 2026-03-26
Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is Principal Consultant at Certify Consulting. With 8+ years of regulatory and quality management experience and a 100% first-time audit pass rate across 200+ clients, Jared provides practical compliance guidance for food, dietary supplement, and medical device manufacturers.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.